Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03116997 · ClinicalTrials.gov registry record · Phase 3
Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant
A Phase 3 study of Surgery, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
- 4
- Study locations
NCT03116997 is a Phase 3 study of Surgery that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 201 participants, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03116997, a Phase 3 study of Surgery, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate and sugammadex) to see if one drug improves patient comfort regarding the return of muscle strength after surgery.
Conditions Studied
Interventions
- DRUG Sugammadex
- DRUG Neostigmine+glycopyrrolate
Study Locations (4)
New York
- Memorial Sloan Kettering Commack - Commack
- Memoral Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
New Jersey
- Memoral Sloan Kettering Basking Ridge - Basking Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2017-04-07 |
| Est. Completion | 2022-03-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03116997
The ClinicalTrials.gov registry entry for NCT03116997 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,850-participant average among 120 other Surgery trials with a reported enrollment target (100% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Surgery appearing as the primary indexed condition, and to 2 interventions - of which Sugammadex is the first listed.
NCT03116997 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT03116997 about?
NCT03116997 is a clinical study titled "Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant". The purpose of this study is to compare two different medications (neostigmine/glycopyrrolate and sugammadex) to see if one drug improves patient comfort regarding the return of muscle strength after surgery.
What is the current status of trial NCT03116997?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2017-04-07. Estimated completion is 2022-03-03.
What conditions does trial NCT03116997 study?
This clinical trial studies the following conditions: Surgery.
What interventions are being tested in trial NCT03116997?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine+glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT03116997?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03116997 being conducted?
This trial has 4 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NO During CPB in Neonates to Reduce Risk of AKI
RECRUITING · Phase 3
-
Sentinel Node Biopsy in Endometrial Cancer
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial
ACTIVE NOT RECRUITING · Phase 3
-
Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo
ACTIVE NOT RECRUITING · Phase 3
-
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.